Thymopoietin Fragment · TP-5
Thymopentin (TP-5) is a synthetic pentapeptide corresponding to amino acids 32-36 (Arg-Lys-Asp-Val-Tyr) of the natural thymic hormone thymopoietin. Thymopoietin is a 49-amino acid polypeptide produced by thymic epithelial cells that plays a critical role in T-cell differentiation and immune regulation. Thymopentin retains the full biological activity of the parent hormone in a much smaller, more stable molecule.
SubQ injection, any time of day. The published trials ran 50 mg three times weekly for six to twelve weeks (Conant 1992, AIDS 6:1335-9, PMID 1361746). Pin alone.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Induces differentiation of immature T-cell precursors (pro-thymocytes) into mature CD4+ and CD8+ T-lymphocytes by mimicking the active site of thymopoietin, promoting expression of T-cell surface markers.
Modulates the balance between T-helper (Th1/Th2) subsets and enhances natural killer (NK) cell activity, improving both cellular immunity and immunosurveillance.
Stimulates production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) while suppressing excessive inflammatory cytokine production, creating a balanced immune response.
Days 1-14: Immune cell differentiation processes begin. No clinically noticeable effects in most patients.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Exact-molecule evidence boundary: the live abstract reports the quoted finding for Thymopentin; no broader inference is made.
Thymopentin (TP-5), the active side of thymopoietin, was shown to affect immunoregulation.
Evidence scope. Exact molecule wording appears in the quoted live sentence. Only the population/model, formulation, route, and outcome expressly stated there are supported.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 50mg; Subcutaneous (SubQ); 3x/week. No selected live abstract sentence verified this complete regimen.
Mechanism as written in source JSON. No selected live abstract sentence verified the complete mechanism at the card formulation/route and relevant population/model.
Primary safety claim as written in source JSON. No selected live abstract sentence verified the complete safety claim for this exact formulation and route.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
SubQ
~5x half-life
SubQ
T-cell differentiation signals persist; supports 3x/week dosing schedule
Enzymatic degradation (endopeptidases and aminopeptidases)
Storage. Store refrigerated at 2-8C. Reconstituted solution should be used within 14 days.
Approved pharmaceutical in China and Italy for immunodeficiency states. Not FDA-approved in the US. Investigated in US clinical trials in the 1980s-1990s.
Put it to work
Open Thymopentin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Thymopentin in the app →Go deeper
The complete Thymopentin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.